Simplify Logo
Sobi

Sobi

Develops therapies for rare diseases

Advocacy and External Relations

Full-TimePosted on 8/19/2026
$150k - $180k/yr

+ Short-term bonus + Long-term bonus + 401(k) match + Recognition awards

Senior
Bachelor's
Waltham, MA, USA
Remote

Travel up to 30% of the time may be required.

About the job

Requirements
  • A BS/BA degree.
  • At least 5 years of relevant experience supporting advocacy, external relations, or patient engagement within the pharmaceutical, biotech, or healthcare industries.
  • Experience supporting advocacy across the pharmaceutical product lifecycle from development through commercialization.
  • Experience in rare disease.
  • Experience building and maintaining relationships with advocacy organizations, policymakers, and professional or medical societies, and identifying opportunities to advance mutual objectives.
  • Working knowledge of the healthcare policy landscape affecting pharmaceutical companies and the patients they serve.
  • Exceptional written, oral communication, and presentation skills.
  • Strong project management skills, including the ability to manage multiple initiatives and stakeholders simultaneously and prioritize delivery of critical outcomes.
  • Experience managing or coordinating with external agencies or vendors.
  • A high level of emotional intelligence demonstrated through strong relationships with a wide range of internal and external stakeholders.
  • Cultural sensitivity and the ability to engage appropriately with people of diverse backgrounds.
  • Ability to travel up to 30% of the time as needed.
Responsibilities
  • Support the development and execution of the strategic external relations and advocacy engagement plan across the development and commercialization continuum, partnering with the Director on program design and budget management.
  • Identify and cultivate relationships with key external partners, including patient advocacy groups, policymakers, and professional organizations, and help identify critical programs and partnership opportunities.
  • Lead the day-to-day execution of initiatives and collaborations with external stakeholders that serve the needs of patients and caregivers, ensuring alignment with corporate values and goals.
  • Collaborate closely with internal cross-functional teams to execute agreed-upon enterprise priorities.
  • Communicate and represent Sobi's commitment to patients and caregivers, supporting the organization's positioning on relevant policy issues.
  • Support relationships with partner organizations by tracking their policy priorities, coordinating logistics for joint meetings and initiatives, and helping align messaging and priorities across partner groups.
  • Coordinate and manage relationships with agencies and vendors supporting advocacy programs, ensuring deliverables are met on time and within scope.
  • Ensure advocacy materials and activities comply with internal review processes.
  • Monitor the external policy and advocacy landscape, flagging relevant developments to the Director of Advocacy and External Relations and the broader team.
Desired Qualifications
  • A master's degree in public health, public policy, or a related field.

About the company

Sobi specializes in developing and delivering therapies for rare diseases. It focuses on hematology, immunology, and specialty care, bringing medicines to patients who have limited treatment options. Their products are designed to treat rare conditions and are typically administered by prescription under medical supervision; the company collaborates with partners to advance research, develop, and commercialize these therapies. Sobi differentiates itself through its strong biotechnological foundation from its Biovitrum heritage and a track record of strategic collaborations with major pharmaceutical players like Sanofi and Apellis, which expand its research capabilities and reach. The company’s goal is to improve the lives of patients with rare diseases worldwide by creating and delivering effective treatments that address unmet medical needs.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Solna kommun, Sweden

Founded

1988

Get referred to Sobi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 revenue grew 24% CER to SEK 7.184 billion, with 63% strategic portfolio mix.
  • Aspaveli gained EU CE certification in May 2026, expanding self-administration across 12-plus indications.
  • Tryngolza advanced with EMA validation and 85% pancreatitis reduction data, supporting 2027 launch potential.

What critics are saying

  • Guido Oelkers leaves by January 2027, forcing a leadership reset during execution-heavy launches.
  • Tryngolza sHTG faces 2027 approval timing; a rejection kills a major growth driver.
  • Arthrosi, Aspaveli, and Gamifant all depend on regulatory wins; one failure compresses valuation fast.

What makes Sobi unique

  • Sobi covers 90% of rare-disease markets by value, spanning Europe, U.S., and Latin America.
  • Its portfolio mixes launched assets, royalties, and late-stage pipeline programs across hematology and immunology.
  • The 2026 Arthrosi acquisition adds gout depth, strengthening a focused rare-disease commercial platform.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Tuition Reimbursement

Wellness Program

Growth & Insights and Company News

Headcount

6 month growth

11%

1 year growth

11%

2 year growth

11%
Nu Pagamentos S.A. (Nubank)
Aug 7th, 2026
Swedish pharma Sobi acquires full control of Latin American oncology specialist Pint Pharma

Swedish biopharmaceutical company Sobi (Swedish Orphan Biovitrum) is acquiring full ownership of Pint Pharma, a firm specialising in bringing complex treatments, including cancer therapies, to Latin American markets. The transaction builds on Sobi's initial investment last year, when it paid $105 million for most of Pint's economic rights. The deal, submitted to Brazil's competition authority Cade, involves purchasing all remaining shares of Pharma Investments, Pint's parent company. The transaction value remains undisclosed. The acquisition gives Sobi control of a platform operating across seven Latin American markets, including Brazil, Mexico, Argentina, and Colombia. Pint handles regulatory approval, market access, and distribution of specialised medicines for rare diseases, haematology, and oncology. Sobi reported revenue of 28.2 billion Swedish kronor (approximately $2.9 billion) in 2025. The companies have maintained a commercial partnership since 2021.

Yahoo Finance
Aug 3rd, 2026
Swedish biopharma Sobi CEO Guido Oelkers to step down by January 2027

Swedish biopharma firm Sobi announced that chief executive Guido Oelkers will step down to take up another position outside the company. Oelkers will continue in his role until the end of January 2027 at the latest. "Leading Sobi has been a privilege, and I am proud of what we have accomplished together as a team," Oelkers said. He highlighted advancing the pipeline, expanding global footprint, and growing Sobi into a leader in rare diseases. The company will immediately begin searching for a new chief executive. Sobi's operations, strategy, and financial targets remain unchanged, the firm said.

PR Newswire
Jul 15th, 2026
Sobi repurchases shares at $0.05 to secure employee incentive programme commitments

Swedish Orphan Biovitrum (Sobi) is repurchasing shares to support its employee incentive programme. The Board of Directors exercised authorisation granted at the May 2026 Annual General Meeting to repurchase class C shares at approximately SEK 0.55 per share, representing 100% of their quotient value. The repurchase involves 223,677 shares and will occur between 16 July and 6 November 2026. Svenska Handelsbanken will handle the transaction. After converting the repurchased class C shares to common shares, Sobi will hold 10,290,974 own shares. The move secures commitments under the All Employee Programme, a long-term incentive scheme for permanent staff. Sobi, a biopharma company focused on rare diseases, employs approximately 2,000 people globally and reported revenue of SEK 28 billion in 2025.

Associated Press
May 22nd, 2026
Enable Injections' enFuse on-body delivery system receives CE certification for Aspaveli in EU

Enable Injections has received CE Certification for its enFuse On-Body Delivery System for use with Aspaveli (pegcetacoplan), which will be distributed by Swedish Orphan Biovitrum across the European Union as ASPAVELI enFuse. The certification allows caregivers and patients aged 12 and older to use the wearable device for subcutaneous drug administration. The enFuse system delivers medication through a discreet, hands-free device using a small, hidden needle, designed to improve patient self-administration. Aspaveli is approved for treating paroxysmal nocturnal haemoglobinuria, C3G and primary IC-MPGN in patients 12 years and older. This follows recent regulatory clearances in Saudi Arabia, Brazil, South Korea and Canada, part of Enable's strategic partnership with Sobi announced in September 2024.

PR Newswire
May 6th, 2026
Sobi AGM approves $2.7B revenue, elects new board members and long-term incentive programmes

Swedish Orphan Biovitrum (Sobi) held its annual general meeting on 6 May 2026, approving several key resolutions. Shareholders adopted the company's financial statements for 2025 and discharged the board and CEO from liability. David Meek was re-elected as board chair, with Christophe Bourdon, Iris Loew-Friedrich, Staffan Schüberg and Filippa Stenberg re-elected as directors. Mikael Dolsten and Åsa Riisberg joined as new board members. Ernst & Young was re-appointed as auditor. The AGM approved long-term incentive programmes, including an employee programme with up to 223,677 series C shares and a management programme via equity swap. The board received authorisation to issue up to 39,710,000 new shares through various instruments. Sobi reported SEK 28 billion in revenue for 2025.

INACTIVE